Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Gavin M. Spencer | CEO & Director | -- | -- | 1970 |
| Ms. Sandrine Gestin | Vice President of Finance & Human Resources | -- | -- | 1967 |
| Mr. Doug Hubatsch | Executive VP & Chief Scientific Officer | -- | -- | 1968 |
| Dr. Ramesh Krishnamoorthy | Senior Director and Head of Late Stage CMC & Quality Control | -- | -- | -- |
| Dr. Jose Boyer | Consultant | -- | -- | -- |
Nicox S.A.
- Full Time Employees:
- 28
Description
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
Corporate Governance
Upcoming Events
April 21, 2025 at 6:30 AM UTC - April 25, 2025 at 6:30 AM UTC
Nicox S.A. Earnings Date
Recent Events
Recent Events Information Not Available